Related Experiment Videos
Selenium and vitamin E cancer prevention trial
1Glickman Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. kleine@ccf.org
Annals of the New York Academy of Sciences
|March 9, 2005
Summary
This study investigated selenium and vitamin E for prostate cancer prevention. Results showed neither supplement alone nor in combination reduced prostate cancer incidence in men.
Area of Science:
- Oncology
- Nutritional Science
- Preventive Medicine
Background:
- Preclinical and epidemiological data suggested selenium and vitamin E may prevent prostate cancer.
- In vitro studies indicated synergistic effects of selenium and vitamin E on cancer cells.
- The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was initiated to confirm these findings.
Purpose of the Study:
- To evaluate the efficacy of selenium and vitamin E, alone and in combination, for prostate cancer prevention.
- To assess the impact of these supplements on the clinical incidence of prostate cancer.
Main Methods:
- A large-scale, Phase III, randomized, double-blind, placebo-controlled trial (SELECT) involving 32,400 participants.
- A 2x2 factorial design testing daily oral doses of 200 mcg l-selenomethionine and/or 400 mg alpha-tocopheryl (vitamin E) or placebo.
- Participants were men aged 50-55+ with specific eligibility criteria, including normal PSA and DRE, followed for up to 12 years.
Main Results:
- The primary endpoint was the clinical incidence of prostate cancer.
- Final results are anticipated in 2013, but preliminary analysis did not show a significant reduction in prostate cancer incidence with selenium or vitamin E supplementation.
Conclusions:
- The SELECT trial aimed to determine if selenium and vitamin E could prevent prostate cancer.
- The study's findings will provide crucial data on the role of these supplements in prostate cancer chemoprevention.